ClickHouse Announces Strategic Collaboration Agreement with AWS to Advance Real-Time Data Analytics and Generative AI Innovation
10.12.2024 15:00:00 CET | Business Wire | Press release
ClickHouse, Inc., a leader in real-time analytics, announced today that it has signed a five-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS), designed to accelerate innovation in real-time data warehousing, observability, business intelligence, machine learning, and generative AI solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210976702/en/
ClickHouse announces strategic collaboration agreement with AWS (Graphic: Business Wire)
The partnership will expand on ClickHouse’s relationship with AWS and introduce new integrations between ClickHouse Cloud and AWS services including Amazon Data Firehose, Amazon Relational Database Service (RDS), AWS Glue, and Amazon Bedrock. Together, this will make it easier for customers to build and manage high-performance analytics and generative AI applications. Additionally, this will provide customers with seamless deployment, enhanced interoperability, and optimal performance of data-intensive workloads powered by ClickHouse on AWS.
In addition to tighter integrations, ClickHouse and AWS will create new tailored industry solutions for customers ranging from finance to e-commerce to gaming. These solutions will enable organizations to harness the power of ClickHouse’s real-time analytics engine alongside AWS services to drive transformational outcomes. The two companies will also work on joint go-to-market activities to empower enterprises with advanced tools to extract actionable insights from their data at scale.
“The reliable infrastructure and global reach of AWS were crucial for the successful launch of ClickHouse Cloud,” said Aaron Katz, CEO of ClickHouse. “Our AWS Marketplace listing significantly expanded our customer reach, while the AWS Partner Network helped us engage with enterprise clients. This led to 150% incremental growth in our customer base on AWS Marketplace in 2024. Now with the strategic collaboration agreement, we strengthen focus on integrations, joint solutions and go-to-market activities to help customers unlock the full potential of their data and drive innovation in their respective industries.”
“We continue to invest in helping growth-stage companies, like ClickHouse, leverage AWS infrastructure, resources, and services like AWS Marketplace to rapidly grow and scale their businesses,” said Julia Chen, Vice President AWS Partner Core. “By integrating ClickHouse Cloud with AWS services such as Amazon Bedrock, customers can leverage the strength of both companies to more easily build advanced real-time applications, such as instant fraud detection, adaptive user experiences, and dynamic operational intelligence—unlocking new possibilities to stay ahead in today’s competitive landscape.”
Helping customers get the best business value from their data lake and data analytics investments is central to the collaboration between ClickHouse and AWS. Since launching ClickHouse Cloud on AWS in 2022, thousands of ClickHouse deployments have already been created, supporting joint customers ranging from startups to Fortune 500 companies. Every day, ClickHouse customers on AWS run over 2 billion queries scanning over 1.5 quadrillion records on top of 50 petabytes of data.
"By migrating our analytics workloads to ClickHouse Cloud on AWS we simplified the integration with data residing in AWS, achieved significant improvement in query performance, and project much lower annual costs. This has let us build new features faster that help our customers better understand their consumers and how their engagement strategies are performing," said Jon Hyman, Cofounder and Chief Technology Officer at Braze [NASDAQ: BRZE].
This collaboration underscores the value of ClickHouse and AWS to provide flexibility and unlock greater business value for customers across industries. For more information please visit: www.clickhouse.com
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank, and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210976702/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom